April 29, 2026 · Phase 3 readout
OCUL Phase 3 readout: a negative outcome, -21.3%
On April 29, 2026, OTX-TKI (axitinib implant) — Ocular Therapeutix, Inc. (Neovascular Age-Related Macular Degeneration) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -21.3% in the window around the event. It had already run -21.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$8.88
1d before
$6.99
Event day
$6.88
1d after
$7.78
5d after
Pre-catalyst setup
-21.2%
30-day run-up
6298%
30-day volatility
0.7×
volume spike